Last updated on August 2018

Open Label Study to Evaluate Safety Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).

Brief description of study

To describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab (AMG 145) when added to standard of care in pediatric subjects 10 to 17 years of age with HeFH or HoFH.

Detailed Study Description

Colombia pending regulatory approval

Clinical Study Identifier: NCT02624869

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Svitavy, Czechia
  Connect »